On behalf of the board of directors, we are grateful to Kevin for taking Better Therapeutics from a
mere idea to a company on the cusp of potentially commercializing our first product and creating a better way to treat metabolic diseases, said David Perry, co-founder and Executive Chairman. And
we are proud to welcome Frank, whose involvement in the launch of three commercial products, success in raising over $4 billion for two public biotech companies and integral role in leading business development activities speak to a track
record of tangible successes in the life sciences industry. Equally important, Franks shared passion for the companys mission to treat the underlying causes of diseases makes him uniquely suited to lead Better Therapeutics.
Earlier this year, Better Therapeutics reported positive primary endpoint data at day 90 evaluating the use of nCBT for the treatment of patients with
uncontrolled type 2 diabetes. The study met its primary efficacy endpoint and demonstrated an excellent safety profile. Patients who received BT-001 demonstrated clinically meaningful and statistically
significant improvement in A1c compared to control (mean improvement 0.4%; p-value < 0.0001). Secondary endpoint data following 180 days of treatment are expected early in Q3, 2022. With continued positive
data, the company expects to file a de novo classification request with the FDA in the third quarter of 2022 seeking marketing authorization of BT-001 for the treatment of patients with type 2 diabetes.
About Better Therapeutics
Better
Therapeutics is a prescription digital therapeutics (PDT) company developing a novel form of cognitive behavioral therapy to address the root causes of cardiometabolic diseases. The company has developed a proprietary platform for the
development of FDA-regulated, software-based solutions for type 2 diabetes, heart disease and other conditions. The cognitive behavioral therapy delivered by Better Therapeutics PDT is designed to enable
changes in neural pathways of the brain so lasting changes in behavior become possible. Addressing the underlying causes of these diseases has the potential to dramatically improve patient health while lowering healthcare costs. Better
Therapeutics clinically validated mobile applications are intended to be prescribed by physicians and reimbursed like traditional medicines.
For
more information visit: bettertx.com
Forward-Looking Statements
Certain statements made in this press release are forward-looking statements within the meaning of the safe harbor provisions under the United
States Private Securities Litigation Reform Act of 1995. Forward-looking statements are typically identified by words such as plan, believe, expect, anticipate, intend, outlook,
estimate, forecast, project, continue, could, may, might, possible, potential, predict, should, would and
other similar words and expressions, but the absence of these words does not mean that a statement is not forward-looking. The forward-looking statements in this press release include, but are not limited to, statements regarding the timing and
results of the ongoing trial of BT-001 in patients with type 2 diabetes, Better Therapeutics plans regarding FDA submissions, the